Chronic Phospholamban Inhibition Prevents Progressive Cardiac Dysfunction and Pathological Remodeling After Infarction in Rats

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2004 Mar 3

PMID 14991071

Citations 57

Authors

Yoshitaka Iwanaga

Masahiko Hoshijima

Yusu Gu

Mitsuo Iwatate

Thomas Dieterle

Yasuhiro Ikeda

Moto-o Date

Jacqueline Chrast

Masunori Matsuzaki

Kirk L Peterson

Kenneth R Chien

John Ross Jr

Affiliations

Soon will be listed here.

Abstract

Ablation or inhibition of phospholamban (PLN) has favorable effects in several genetic murine dilated cardiomyopathies, and we showed previously that a pseudophosphorylated form of PLN mutant (S16EPLN) successfully prevented progressive heart failure in cardiomyopathic hamsters. In this study, the effects of PLN inhibition were examined in rats with heart failure after myocardial infarction (MI), a model of acquired disease. S16EPLN was delivered into failing hearts 5 weeks after MI by transcoronary gene transfer using a recombinant adeno-associated virus (rAAV) vector. In treated (MI-S16EPLN, n = 16) and control (MI-saline, n = 18) groups, infarct sizes were closely matched and the left ventricle was similarly depressed and dilated before gene transfer. At 2 and 6 months after gene transfer, MI-S16EPLN rats showed an increase in left ventricular (LV) ejection fraction and a much smaller rise in LV end-diastolic volume, compared with progressive deterioration of LV size and function in MI-saline rats. Hemodynamic measurements at 6 months showed lower LV end-diastolic pressures, with enhanced LV function (contractility and relaxation), lowered LV mass and myocyte size, and less fibrosis in MI-S16EPLN rats. Thus, PLN inhibition by in vivo rAAV gene transfer is an effective strategy for the chronic treatment of an acquired form of established heart failure.

Citing Articles

Isoproterenol mechanisms in inducing myocardial fibrosis and its application as an experimental model for the evaluation of therapeutic potential of phytochemicals and pharmaceuticals.

Bader Eddin L, Nagoor Meeran M, Jha N, Goyal S, Ojha S Animal Model Exp Med. 2024; 8(1):67-91.

PMID: 39690876 PMC: 11798751. DOI: 10.1002/ame2.12496.

Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Luraghi A, Ferrandi M, Barassi P, Arici M, Hsu S, Torre E J Med Chem. 2022; 65(10):7324-7333.

PMID: 35580334 PMC: 9150102. DOI: 10.1021/acs.jmedchem.2c00347.

Targeting calcium-mediated inter-organellar crosstalk in cardiac diseases.

Hulsurkar M, Lahiri S, Karch J, Wang M, Wehrens X Expert Opin Ther Targets. 2022; 26(4):303-317.

PMID: 35426759 PMC: 9081256. DOI: 10.1080/14728222.2022.2067479.

Mitochondria Isolated from Hearts Subjected to Ischemia/Reperfusion Benefit from Adenine Nucleotide Translocase 1 Overexpression.

Dorner A, Lynetskiy O, Euler G, Landmesser U, Schluter K, Heger J Membranes (Basel). 2021; 11(11).

PMID: 34832065 PMC: 8619488. DOI: 10.3390/membranes11110836.

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy.

Grote Beverborg N, Spater D, Knoll R, Hidalgo A, Yeh S, Elbeck Z Nat Commun. 2021; 12(1):5180.

PMID: 34462437 PMC: 8405807. DOI: 10.1038/s41467-021-25439-0.

References

Minamisawa S, Hoshijima M, Chu G, Ward C, Frank K, Gu Y . Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999; 99(3):313-22. DOI: 10.1016/s0092-8674(00)81662-1. View

Picard M, Wilkins G, Ray P, Weyman A . Natural history of left ventricular size and function after acute myocardial infarction. Assessment and prediction by echocardiographic endocardial surface mapping. Circulation. 1990; 82(2):484-94. DOI: 10.1161/01.cir.82.2.484. View

Ikeda Y, Martone M, Gu Y, Hoshijima M, Thor A, Oh S . Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol. 2000; 278(4):H1362-70. DOI: 10.1152/ajpheart.2000.278.4.H1362. View

Eizema K, Fechner H, Bezstarosti K, van der Laarse A, Wang H, Schultheiss H . Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation. 2000; 101(18):2193-9. DOI: 10.1161/01.cir.101.18.2193. View

Marx S, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N . PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000; 101(4):365-76. DOI: 10.1016/s0092-8674(00)80847-8. View

Zhou Y, Wang S, Zhu W, Chruscinski A, Kobilka B, Ziman B . Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol. 2000; 279(1):H429-36. DOI: 10.1152/ajpheart.2000.279.1.H429. View

Frey N, McKinsey T, Olson E . Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000; 6(11):1221-7. DOI: 10.1038/81321. View

Frank K, Tilgmann C, Shannon T, Bers D, Kranias E . Regulatory role of phospholamban in the efficiency of cardiac sarcoplasmic reticulum Ca2+ transport. Biochemistry. 2000; 39(46):14176-82. DOI: 10.1021/bi001049k. View

Brittsan A, Kranias E . Phospholamban and cardiac contractile function. J Mol Cell Cardiol. 2000; 32(12):2131-9. DOI: 10.1006/jmcc.2000.1270. View

10.

Hongo M, Ryoke T, Schoenfeld J, Hunter J, Dalton N, Clark R . Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol. 2001; 95(6):431-41. DOI: 10.1007/s003950070018. View

11.

Bartlett J . Gene therapy: recombinant adeno-associated virus vectors. Curr Cardiol Rep. 2001; 3(1):43-9. DOI: 10.1007/s11886-001-0009-x. View

12.

Molkentin J, Dorn 2nd G . Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63:391-426. DOI: 10.1146/annurev.physiol.63.1.391. View

13.

Auricchio A, Hildinger M, OConnor E, Gao G, Wilson J . Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 2001; 12(1):71-6. DOI: 10.1089/104303401450988. View

14.

Shah A, White D, Emani S, Kypson A, Lilly R, Wilson K . In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001; 103(9):1311-6. DOI: 10.1161/01.cir.103.9.1311. View

15.

Somia N, Verma I . Gene therapy: trials and tribulations. Nat Rev Genet. 2001; 1(2):91-9. DOI: 10.1038/35038533. View

16.

Freeman K, Lerman I, Kranias E, Bohlmeyer T, Bristow M, Lefkowitz R . Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001; 107(8):967-74. PMC: 199560. DOI: 10.1172/JCI12083. View

17.

Hosenpud J, Bennett L, Keck B, Boucek M, Novick R . The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. J Heart Lung Transplant. 2001; 20(8):805-15. DOI: 10.1016/s1053-2498(01)00323-0. View

18.

Del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey J . Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001; 104(12):1424-9. PMC: 1249503. DOI: 10.1161/hc3601.095574. View

19.

Marks A, Priori S, Memmi M, Kontula K, Laitinen P . Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. J Cell Physiol. 2002; 190(1):1-6. DOI: 10.1002/jcp.10031. View

20.

Ikeda Y, Gu Y, Iwanaga Y, Hoshijima M, Oh S, Giordano F . Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation. 2002; 105(4):502-8. DOI: 10.1161/hc0402.102953. View